Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post-herpetic Neuralgia Clear all
Completed Phase 2 Interventional

Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia

NCT00478179
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
Transdermal/Patch (Bupivacaine TTS [Eladur™])
Drug
Lead sponsor
Durect
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
La Jolla, California • Loma Linda, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2009 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

NCT01688947
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
V116517 50-mg tablets, V116517 30-mg tablets, Pregabalin capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
21 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
28
States / cities
Tucson, Arizona • La Jolla, California • North Hollywood, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 15, 2026, 7:52 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia.

NCT07599800
View directory record Official record
Conditions
PHN - Post-Herpetic Neuritis
Interventions
APC101, Control
Drug · Other
Lead sponsor
Andros Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Florida City, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Terminated Phase 2 Interventional

A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.

NCT00353808
View directory record Official record
Conditions
Pain
Interventions
[S,S]-Reboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
57
States / cities
Huntsville, Alabama • Chandler, Arizona • Gilbert, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 2 Interventional

Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)

NCT00609323
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
lidocaine and tetracaine cream 7%/7%, Placebo
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Lexington, Kentucky • High Point, North Carolina • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

NCT01129531
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
AGN-214868, Placebo to AGN-214868
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 2 Interventional

Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain

NCT00034710
View directory record Official record
Conditions
Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
Interventions
Capsaicin Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
8
States / cities
Phoenix, Arizona • Tucson, Arizona • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2006 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Not applicable Interventional Results available

Transcranial Magnetic Stimulation for Facial Pain

NCT02633306
View directory record Official record
Conditions
Trigeminal Nerve Injuries, Post-herpetic Neuralgia, Facial Pain, Nervus Intermedius Neuralgia
Interventions
transcranial magnetic stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 110 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)

NCT00592774
View directory record Official record
Conditions
Neuralgia
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
42
States / cities
Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 15, 2026, 7:52 PM EDT
Terminated Phase 2 Interventional

[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.

NCT00354094
View directory record Official record
Conditions
Pain
Interventions
[S,S]-Reboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Tampa, Florida • West Palm Beach, Florida • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2007 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia

NCT04662281
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Placebo, LX9211
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Scottsdale, Arizona • Tucson, Arizona • Greenbrae, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Results available

Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

NCT01270828
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
Pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
82
States / cities
Gulf Shores, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 15, 2026, 7:52 PM EDT
Completed No phase listed Observational Results available

Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia

NCT01426230
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
Not listed
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
37
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Not applicable Interventional

Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain

NCT04144972
View directory record Official record
Conditions
Spinal Cord Injuries, Nerve Injury, Pain, Postoperative, Post Herpetic Neuralgia, Complex Regional Pain Syndromes, Post-Stroke Pain, Post Radiation Brain Injury, Post Radiation Plexopathy, Nerve Root Avulsion
Interventions
Medtronic Summit RC+S or Percept RC
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

NCT00612105
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Retigabine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Vaporized Marijuana on Neuropathic Pain

NCT01037088
View directory record Official record
Conditions
Neuropathic Pain, Reflex Sympathetic Dystrophy, Peripheral Neuropathy, Post-herpetic Neuralgia, Spinal Cord Injury, Multiple Sclerosis
Interventions
Mild dose cannabis, Low dose cannabis, Cannabis
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 2 Interventional

Evaluation of Civamide Patch in Treatment of Postherpetic Neuralgia and Post-Incisional Neuralgia

NCT00845923
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Civamide Patch
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Sunrise, Florida • Chicago, Illinois • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Sep 15, 2026, 7:52 PM EDT
Terminated Phase 2 Interventional

Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

NCT00809679
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
T-62 Dose 1, T-62 Dose 2, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Tucson, Arizona • Westlake Village, California • Bradenton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Results available

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

NCT00415597
View directory record Official record
Conditions
Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 4 Interventional

A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

NCT00904020
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Low Back Pain
Interventions
Lidoderm
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Plantation, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 15, 2026, 7:52 PM EDT
Withdrawn Phase 2 Interventional

A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak

NCT00506610
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
T-62
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Bradenton, Florida • Naples, Florida • New Port Richey, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

NCT00343733
View directory record Official record
Conditions
Pain
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
21
States / cities
Hot Springs, Arkansas • Los Gatos, California • Oxnard, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 2 Interventional

Crossover Post-herpetic Neuralgia (PHN)

NCT01305538
View directory record Official record
Conditions
Post-Herpetic Neuralgia (PHN)
Interventions
BMS-954561, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Phoenix, Arizona • Lomita, California • Boulder, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 15, 2026, 7:52 PM EDT
Not listed Phase 2 Interventional

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

NCT00099528
View directory record Official record
Conditions
Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions
REN-1654
Drug
Lead sponsor
Renovis
Industry
Eligibility
55 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2010 · Synced Sep 15, 2026, 7:52 PM EDT